The Stanley Medical Research Institute (SMRI) is a nonprofit organization supporting research on the causes of, and treatments for, schizophrenia and bipolar disorder. Since it began in 1989, SMRI has supported more than $300 million in research in over 30 countries around the world. It is the largest nongovernmental source of funds for research on these diseases in the United States.
Schizophrenia and bipolar disorder are the most important psychiatric disorders in the United States, affecting more than 4 million people at any given time. Until recent years, little research had been done on these diseases, and the treatment of them was unsatisfactory. The neuroscience revolution has brought with it great opportunities for increased understanding of brain diseases such as schizophrenia and bipolar disorder. SMRI is on the leading edge of this exciting research.
Approximately 75 percent of SMRI expenditures goes towards the development of new treatments for schizophrenia and bipolar disorder. The remaining funds are used for research on the causes of these diseases.
Repurposed drugs, which are approved for other medical conditions, are a potential therapeutic resource for patients who have not responded to other drugs. SMRI has developed a Repurposed Drugs Database to provide current updates on 9 repurposed drugs which SMRI has supported treatment trials for.
SMRI has a close relationship with and is the supporting organization for the Treatment Advocacy Center (TAC). The Treatment Advocacy Center is a nonprofit organization dedicated to eliminating barriers to the timely and effective treatment of severe psychiatric disorders. TAC promotes laws, policies, and practices for the delivery of psychiatric care and supports the development of innovative treatments for and research into the causes of severe and persistent psychiatric disorders, such as schizophrenia and bipolar disorder.